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SUMMARY
Long-term use of non-steroidal anti-inﬂammatory drugs
(NSAIDs) increases the risk of serious gastroduodenal
events. To minimise these risks, patients often require
concomitant acid-suppressive therapy. We conducted a
literature review of clinical trials examining use of raniti-
dine 150 mg twice daily to heal gastroduodenal ulcers
(GU) in NSAID recipients. Seven studies were identi-
ﬁed. After 8 weeks’ treatment with ranitidine, GU heal-
ing rates ranged from 50% to 74% and rates of
duodenal ulcer (DU) healing ranged from 81% to 84%.
Ranitidine was more effective when NSAIDs were dis-
continued (healing rates reaching 95% and 100%,
respectively). The ulcer healing rate with sucralfate was
similar to that of ranitidine. However, proton pump
inhibitor (PPI) therapy was associated with signiﬁcantly
greater rates of both GU and DU healing than raniti-
dine; 8-week GU rates were 92% and 88% with eso-
meprazole 40 mg and 20 mg, respectively (vs. 74% with
ranitidine, p 0 0.01). For omeprazole, 8-week healing
rates were 87% with omeprazole 40 mg and 84% with
omeprazole 20 mg (vs. 64% for ranitidine, p 0 0.001),
and for lansoprazole the corresponding values were 73–
74% and 66–69% for the 30 mg and 15 mg doses,
respectively (vs. 50–53% for ranitidine, p 0 0.05). In
the PPI study reporting DU healing the values were
92% for omeprazole 20 mg (vs. 81% for ranitidine,
p 0 0.05) and 88% for omeprazole 40 mg (p ¼ 0.17
vs. ranitidine). NSAID-associated GU are more likely to
heal when patients receive concomitant treatment with a
PPI rather than ranitidine.
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INTRODUCTION
Non-steroidal anti-inﬂammatory drugs (NSAIDs) are pri-
marily prescribed for painful conditions, such as osteoarthri-
tis and rheumatoid arthritis (1), and are among the most
widely prescribed medications used today (2). Although the
elderly (aged  65 years of age) receive the bulk of NSAID
prescriptions (3), use of NSAIDs is increasing in a wider
range of age groups because of the growing use of low-dose
aspirin for the prevention of thrombotic conditions (4) and
frequent use of over-the-counter NSAIDs for general pain
relief (5).
Despite their widespread use and beneﬁcial effects,
NSAIDs increase the risk of gastroduodenal ulcers (GU)
(6), the consequences of which can sometimes be life-threat-
ening bleeding or perforation (7,8). Advanced age is an
independent risk factor for the development of GU (9,10).
Not surprisingly, GU are a particular problem among
patients suffering from arthritic conditions, the majority of
whom are elderly and require long-term NSAID therapy.
Research shows that the incidence of serious complications
of GU is continuing to rise among older individuals (11).
The most obvious method of controlling NSAID-associ-
ated upper gastrointestinal (GI) toxicity is NSAID with-
drawal, but consequent deterioration in the underlying
condition and increased pain may make this option undesir-
able (12). Another preventative option involves the use of
cyclooxygenase (COX)-2-selective rather than non-selective
NSAIDs. Relative to non-selective NSAIDs, COX-2-select-
ive agents are associated with a reduced incidence of serious
upper GI adverse events (13,14), but do not eliminate
them, particularly in high-risk patients (15,16). Further-
more, concerns about increases in cardiovascular risks have
led to re-evaluation of the use of COX-2-selective NSAIDs
in clinical practice, and the withdrawal of certain COX-2
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being urged not to use the remaining marketed COX-2-
selective NSAIDs unless absolutely necessary (17). Such
restrictions are likely to lead to many patients returning to
treatment with a non-selective NSAID.
Overall, the most effective and satisfactory option to help
prevent initial occurrence of NSAID-associated GU, heal
existing ulcers and prevent ulcer recurrence is co-prescrip-
tion of a gastroprotective acid-suppressive agent (18–20).
This strategy should, in many cases, allow patients to receive
long-term NSAID therapy more safely at the most appro-
priate dose to alleviate their underlying inﬂammatory condi-
tion. Classes of acid-suppressive treatments for NSAID-
associated GU include histamine H2 receptor antagonists
(H2RAs) and proton pump inhibitors (PPIs). PPIs have
been shown to be very effective in reducing the risk of
developing GU, therefore it may be desirable for patients
taking NSAIDS to also take a PPI to prevent ulcers forming
(19,21–23). Additionally, cytoprotective agents such as suc-
ralfate can be used to heal GU, and the prostaglandin ana-
logue misoprostol can be used to help prevent NSAID-
associated ulcers (12). Notably, misoprostol is the only
agent that has been shown to reduce the risk of complica-
tions arising from NSAID-associated ulcers (24), but the
drug is associated with adverse events such as diarrhoea,
abdominal pain and increased uterine contractility (12).
Although it is known that H2RAs provide less effective acid
suppression than PPIs (25), the H2RA ranitidine has been
widely studied in the treatment of acid-related disorders,
including GU and serves as a useful ‘yardstick’ when compar-
ing the efﬁcacy of various agents. Of the H2RA class of drugs,
ranitidine has also been the agent most extensively studied
for the speciﬁc indication of healing NSAID-associated ulcers.
This review focuses on clinical trials in which ranitidine has
been used in the treatment of NSAID-associated GU.
We conducted a search of PubMed using the Medical
Subject Headings terms ‘NSAID’ and ‘ranitidine’, as well as
the text word ‘ulcer healing’. The search was limited to
manuscripts detailing clinical trials, up to March 2006. Of
these, only manuscripts that focused on the use of ranitidine
in the treatment of NSAID-associated GU were selected.
RESULTS
Manuscripts Included
Using the search criteria, 33 manuscripts were retrieved from
PubMed. Seven of these were selected as being focused spe-
ciﬁcally on the use of ranitidine 150 mg twice daily (bid) for
healing NSAID-associated GU (19,26–31). The main char-
acteristics of the studies are summarised in Table 1. In gen-
eral, ulcers were considered healed when endoscopy revealed
complete re-epithelialisation of the mucosa.
One of the trials identiﬁed during our literature search
was a 4-week trial performed by Tildesley et al. (29). This
was a multinational, multicentre, randomised, double-blind,








Goldstein et al. (26) Gastric ulcer and continuous NSAID
(n ¼ 399; mean age: 58 years)
150 Esomeprazole (20 mg or
40 mg qd)
8
Campbell et al. (27) Gastric ulcer and continuous NSAID
(n ¼ 692; mean age: 58 years)
150 Lansoprazole (15 mg or
30 mg qd)
8
Agrawal et al. (28) Gastric ulcer and continuous NSAID
(n ¼ 353; mean age: 60 years)
150 Lansoprazole (15 mg or
30 mg qd)
8
Yeomans et al. (19) Gastric/duodenal ulcer or 110 erosions
in the stomach or duodenum and
continuous NSAID (n ¼ 541; mean
age: 57 years)
150 Omeprazole (20 mg or
40 mg qd)
8
Tildesley et al. (29) Gastric/duodenal ulcer or 110 erosions
in the stomach or duodenum. Continuing
or stopping NSAID (n ¼ 243; mean age:
56 years)
150 Placebo without NSAID 4
Lancaster-Smith et al. (30) Gastric/duodenal ulcer. Continuing or
stopping NSAID (n ¼ 190; mean age:
65 years)
150 –  12
Manniche et al. (31) Gastric/duodenal ulcer and continuous
NSAID (n ¼ 67; median age RA: 67;
non-RA: 71)
150 Sucralfate (1 g qid)  9
bid, twice daily; NSAID, non-steroidal anti-inﬂammatory drugs; qd, once daily; qid, four times daily; RA, rheumatoid arthritis.
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duodenal damage, 149 of whom had gastric and/or duode-
nal ulceration of  5 mm in diameter, associated with
current NSAID use. Patients were randomly assigned to
receive ranitidine with either continued NSAID use (n ¼
99; n ¼ 62 with ulcers), NSAID use discontinued (n ¼ 94;
n ¼ 61 with ulcers) or to placebo with discontinuation of
NSAID medication (n ¼ 50; n ¼ 26 with ulcers).
Manniche et al. (31) conducted a randomised open-label
study that compared ranitidine (n ¼ 32) with sucralfate 1 g
four times daily (qid) (n ¼ 30) in patients aged 35–
87 years, diagnosed with a GU of 13 mm diameter. Half
of the patients in each treatment group continued with
NSAID therapy while the other half was given alternative
analgesic treatment. Patients had been receiving NSAID
treatment for a mean of 15 years for rheumatoid arthritis
(n ¼ 38), osteoarthritis (n ¼ 24) or other rheumatic condi-
tions (n ¼ 5). If, after 9 weeks of treatment, ulcer healing
was not achieved then patients were switched to receive the
other anti-ulcer therapy.
In a multicentre, open-label study by Lancaster-Smith
et al. (30), 190 patients who were receiving NSAIDs for
arthritic conditions and who had at least one gastric and/or
duodenal ulcer (DU) of  5 mm in diameter were random-
ised to continue (n ¼ 96) or stop (n ¼ 94) NSAID treat-
ment. All patients were treated with ranitidine for 12 weeks.
The report by Campbell et al. (27) is an analysis of two
multicentre, randomised, double-blind trials, one of which
is reported separately in the manuscript by Agrawal et al.
(28). In these studies, which compared 8 weeks’ treatment
with ranitidine (n ¼ 231), lansoprazole 15 mg once daily
(qd) (n ¼ 232) or lansoprazole 30 mg qd (n ¼ 229),
patients had at least one gastric ulcer of  5 mm in diam-
eter at the start of the study. Patients with multiple gastric
ulcers, coexisting DU or coexisting erosive oesophagitis were
also eligible to participate in the study. Patients were aged
 18 years and had been receiving a stable daily dose of
NSAID treatment for  1 month before enrolment. The
primary indication for NSAID use in both studies was arth-
ritis.
In their multicentre, randomised, double-blind study,
Goldstein et al. (26) assessed gastric ulcer healing after 4
and 8 weeks’ treatment with ranitidine (n ¼ 132), esomep-
razole 20 mg qd (n ¼ 138) or esomeprazole 40 mg qd
(n ¼ 129). Again, to be included in the study, patients were
required to be aged  18 years, have at least one gastric
ulcer of  5 mm in diameter at baseline and to have been
receiving a stable daily dose of NSAID treatment for
 1 month prior to enrolment. Patients were permitted to
have multiple gastric ulcers and concurrent DU, provided
that each ulcer was  25 mm at its greatest diameter.
NSAIDs were being used predominantly to treat osteoarth-
ritis (n ¼ 233).
In another multinational, multicentre, randomised, dou-
ble-blind study, Yeomans et al. (19) assessed the efﬁcacy of
4–8 weeks’ ranitidine (n ¼ 174), omeprazole 20 mg qd
(n ¼ 174) and omeprazole 40 mg qd (n ¼ 187) in patients
who had at least one GU of  3 mm in diameter and/or
multiple gastroduodenal erosions. Patients aged between 18
and 85 years who had any condition requiring continuous
treatment with daily NSAIDs were assessed for inclusion in
the study. Most patients had rheumatoid arthritis (n ¼
234) or osteoarthritis (n ¼ 182).
Patients’ Helicobacter pylori status was assessed by biopsy
in four of the studies selected for inclusion in this report
(19,26–28). The proportions of patients who were
H. pylori-positive in each of these studies was 19% (26),
26% (27), 29% (28) and 46% (19).
Ranitidine Healing Rates
The gastric ulcer healing rates associated with the use of
ranitidine in patients continuing to take NSAIDs are shown
in Figure 1A. Most variation was observed for healing rates at
4 weeks, which ranged from 30% to 67%. Even after
8 weeks, endoscopic examination revealed that approxi-
mately one-quarter to one-half of patients treated with
ranitidine still had unhealed ulcers (healing rates of 50–74%).
Duodenal ulcer healing rates obtained with ranitidine in
patients continuing to take NSAIDs (Figure 1B) were gen-
erally higher than those for gastric ulcers. At 4 weeks, DU
healing rates ranged from 57% to 74%, increasing to
between 81% and 84% at 8 weeks. However, in the study
by Tildesley et al. (29) a slightly higher 4-week healing rate
was observed for gastric ulcers over DUs (67% vs. 61%).
The study report by Manniche et al. (31) only gives over-
all GU healing rates by treatment group. These results show
comparable healing rates between ranitidine and sucralfate
of 84% and 83%, respectively. The respective mean times
to ulcer healing were 4.9 weeks and 4.6 weeks. In this same
study for the combined treatment groups, a higher percent-
age of patients who continued NSAID therapy had DU
healing (83%) than gastric ulcer healing (50%). For patients
who were withdrawn from NSAIDs, respective duodenal
and gastric ulcer healing rates were 92% and 86%.
Effect of NSAID Withdrawal on Healing Rates
Use of ranitidine was compared with placebo in the study
by Tildesley et al. (29). Discontinuation of NSAID therapy
in patients receiving ranitidine resulted in a higher rate of
healing for patients with DU but not for those with gastric
ulcers, and ranitidine was only associated with a signiﬁcantly
higher 4-week rate of healing than placebo in patients with
DU in whom NSAIDs were discontinued (81% vs. 42%;
p 0 0.05). In the study by Lancaster-Smith et al., in which
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parator (30), discontinuation of NSAIDs improved healing
of gastric ulcer and DU. After 8 weeks of treatment, gastric
ulcers had healed in 95% of patients who had stopped
NSAID therapy compared with 63% in patients continuing
NSAIDs (p ¼ 0.001). For DU, the healing rates were
100% and 84% in patients who had ceased or continued
NSAIDs, respectively (p ¼ 0.006). Similar trends were
observed for gastric ulcers and DUs treated with ranitidine
or sucralfate in the trial by Manniche et al. (31). In this
study, GU healing rates were 77% in patients who contin-
ued to take NSAIDs and 91% in patients in whom
NSAIDs were withdrawn (p 1 0.10).
Comparator Healing Rates
Manniche et al. (31) found that the rate of GU healing
obtained with sucralfate was similar to that obtained with
ranitidine (83% and 84%, respectively). These rates were
obtained in a mixture of patients who continued to take
NSAID medication and those who discontinued NSAID
therapy.
Of the six manuscripts included in this report, four com-
pared ranitidine with PPIs; one using esomeprazole (20 mg
or 40 mg qd) (26), one using omeprazole (20 mg or 40 mg
qd) (19) and two using lansoprazole (15 mg or 30 mg qd)
(27,28). Four- and 8-week healing rates for ranitidine vs.
esomeprazole, omeprazole and lansoprazole are shown in
Figure 2.
Compared with the ranitidine treatment group at both
the 4- and 8-week assessments, gastric ulcer healing
occurred in signiﬁcantly higher proportions of patients trea-
ted with either the 20 mg dose of esomeprazole or the
40 mg dose (Figure 2A). At the end of the 8-week treat-
ment period, the healing rate was 74% with ranitidine com-
pared with 88% with esomeprazole 20 mg (p 0 0.01) and
92% with esomeprazole 40 mg (p 0 0.001).
Statistical analysis of the 8-week data showed a signiﬁcant
difference in favour of both omeprazole doses for healing
gastric ulcers and for omeprazole 20 mg for healing DU,
relative to ranitidine (Figure 2B). After 8 weeks of treat-
ment with the 20 mg omeprazole dose, gastric ulcer healing
occurred in 84% of patients and DU healing was observed
in 92% of patients compared with 64% of gastric ulcer
(p 0 0.001) and 81% of DU (p 0 0.05) patients treated
with ranitidine. Numerically higher healing rates were
observed with both doses of omeprazole relative to raniti-
dine after 4 weeks of treatment.
In the two papers that investigated ranitidine in compar-
ison with lansoprazole, both doses of the PPI were found to
be signiﬁcantly more effective than ranitidine for providing
healing of gastric ulcers after both 4 and 8 weeks of treat-
ment (Figure 2C). The 8-week gastric ulcer healing rates
were 73% (28) and 74% (27) in patients treated with lan-
soprazole 30 mg, relative to respective healing rates of 53%
(p 0 0.01) and 50% (p 0 0.001) for patients treated with
ranitidine.
Effect of H. pylori On Healing Rates
The rates of H. pylori infection were 19% in the paper
comparing ranitidine and esomeprazole (26), 26% and 29%
in the two papers comparing ranitidine and lansoprazole
(27,28), and 46% in the study comparing ranitidine and
omeprazole (19). Campbell et al., Goldstein et al. and Yeo-
mans et al. all reported that H. pylori-positive patients were
more likely to be healed during 8 weeks of treatment than
H. pylori-negative patients. Yeomans et al. reported that
Figure 1 Four-, 8- and 12-week NSAID-associated ulcer healing rates for (A) gastric ulcers and (B) duodenal ulcers in patients taking
ranitidine 150 mg twice daily
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H. pylori-positive and 75% of H. pylori-negative patients
receiving omeprazole 20 mg, 82% and 71% of the respective
groups of patients receiving omeprazole 40 mg, and 72%
and 55% of those receiving ranitidine (p ¼ 0.05 for the
overall likelihood of successful healing in H. pylori-positive
vs. H. pylori-negative patients).
DISCUSSION
Our review is focused on ranitidine, at a dose of 150 mg
bid, because this therapy is widely used for treating GU
associated with NSAIDs and a sufﬁcient number of primary
healing studies have been conducted with this agent to sup-
port such a review. The overall ﬁndings of the review show
that ranitidine has similar efﬁcacy to sucralfate for healing
GU, but provides less effective ulcer healing than PPIs dur-
ing continuous NSAID therapy. Ulcers heal most readily
with ranitidine when NSAIDs are discontinued. After
8 weeks of treatment during continuous NSAID therapy,
PPIs are capable of producing GU healing rates that are up
to 20% greater than rates obtained with ranitidine.
Healing rates associated with ranitidine treatment were
found to vary markedly between studies, with Goldstein
et al. (26) and Tildesley et al. (29) reporting 4-week gastric
ulcer healing rates in patients continuing NSAID therapy
that were more than twice those reported by Campbell
et al. (27) and Agrawal et al. (28). Additionally, the 8-week
gastric ulcer healing rate reported by Goldstein et al. was
more than 20% greater than those reported with ranitidine
in these other two studies. The reasons for this are unclear
because all of these studies used the same ulcer deﬁnition
( 5 mm in diameter), but were most likely related to dif-
ferences in the patient populations.
Although there are few published studies examining the
use of other H2RAs in NSAID-associated ulcer healing,
healing rates have been reported in association with com-
pounds such as famotidine, nizatidine and cimetidine. In a
study by Hudson et al. (32), famotidine 40 mg bid was
assessed for NSAID-associated GU healing in arthritic
Figure 2 Four- and 8-week gastric and duodenal ulcer healing rates in studies comparing ranitidine 150 mg twice daily (bid) with the
proton pump inhibitors (A) esomeprazole once daily (qd) (26), (B) omeprazole (qd) (19) or (C) lansoprazole (qd) (27,28). The manuscript
by Campbell et al. (27) includes the study by Agrawal et al. (28) as part of a pooled analysis with a separate study. *p 0 0.05,
**p 0 0.01, ***p 0 0.001, p ¼ 0.17
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therapy. Over the relatively long 12-week treatment period,
the healing rate was 89% in patients continuing NSAID
therapy. It should, however, be noted that the standard
famotidine dose is 20 mg bid rather than 40 mg bid. In
another study involving patients with NSAID-associated
GU, three different regimens of nizatidine therapy led to
over 90% of patients being healed at 8 weeks (33). In addi-
tion, cimetidine 800 mg/day led to a 49% peptic ulcer heal-
ing rate at 4 weeks and a 81% healing rate at 8 weeks in
patients with GU associated with continuous NSAID use
(34). It should be noted that inclusion criteria for these
studies allowed for patients with quite small ulcers (as small
as about 3 mm in diameter), which may have rendered
them easier to treat than in a number of the studies inclu-
ded in this review that speciﬁed an ulcer diameter of
 5 mm. Additionally, the absence of placebo or other con-
trol groups in these studies of other H2RAs limits interpret-
ation and detracts from the relevance of the results.
The degree of gastroduodenal damage caused by NSAIDs
is highly dependent upon intragastric pH (35–37). It is well
established that H2RAs provide less effective acid suppres-
sion over a 24-h period than PPIs (38). The increased heal-
ing rates observed with PPI therapy relative to ranitidine in
the studies included in this review are consistent with GU
healing being directly related to the degree of acid suppres-
sion obtained with acid-suppressive drugs (39).
The contribution made by H. pylori to the risk of
NSAID-associated ulcers is still controversial (40). Historic-
ally, H. pylori infection has been shown to be a risk factor
for the development of GU (41). However, H. pylori may
have a mixed role in NSAID-associated ulcer healing as
infection increases the acid-suppressive effect of PPIs (42)
and also seems to stimulate synthesis of prostaglandin E2 by
promoting mucosal inﬂammatory cell inﬁltration (43). In
contrast, NSAIDs act to depress prostaglandin levels (44),
thereby compromising protection of the gastroduodenal
mucosa against gastric acid (45). The results of the relevant
studies included in this review suggest that successful heal-
ing of GU may occur most readily in H. pylori-positive
patients, regardless of the type of treatment. However, the
extent of the risk or beneﬁt associated with H. pylori infec-
tion for patients taking NSAIDs has yet to be fully estab-
lished (19).
CONCLUSION
The results of this review show that, in patients with
NSAID-associated GU, for whom discontinuation of
NSAID therapy is not appropriate, PPIs, which offer more
substantial acid suppression than H2RAs, are associated with
higher rates of ulcer healing than ranitidine at the standard
dose of 150 mg bid.
ACKNOWLEDGEMENT
This study was supported by AstraZeneca. We thank Cathy
Baker and Steve Winter from Wolters Kluwer Health, who
provided medical writing support funded by AstraZeneca.
REFERENCES
1 Cullen DJ, Seager JM, Holmes S et al. Pharmacoepidemiology
of non-steroidal anti-inﬂammatory drug use in Nottingham
general practices. Aliment Pharmacol Ther 2000; 14: 177–85.
2 Jones R. Nonsteroidal anti-inﬂammatory drug prescribing:
past, present and future. Am J Med 2001; 110: 4S–7S.
3 Tenenbaum J. The epidemiology of nonsteroidal anti-inﬂam-
matory drugs. Can J Gastroenterol 1999; 13: 119–22.
4 Bedson J, Whitehurst T, Lewis M et al. Factors affecting over-
the-counter use of aspirin in the secondary prophylaxis of car-
diovascular disease. Br J Gen Pract 2001; 51: 1001–3.
5 Thomas J, Strauss WL, Bloom BS. Over-the-counter nonste-
roidal anti-inﬂammatory drugs and risk of gastrointestinal
symptoms. Am J Gastroenterol 2002; 97: 2215–9.
6 Laine L. The gastrointestinal effects of non-selective and
COX-2-selective inhibitors. Semin Arthritis Rheum 2002; 32
(3 Suppl. 1): 25–32.
7 Arlt GD, Leyh M. Incidence and pathophysiology of peptic
ulcer bleeding. Langenbeck’s Arch Surg 2001; 386: 75–81.
8 Buttgereit F, Burmster GR, Simon LS. Gastrointestinal toxic
side effects of nonsteroidal anti-inﬂammatory drugs and cyclo-
oxygenase-2-speciﬁc inhibitors. Am J Med 2001; 110 (Suppl.
3A): 13S–9 .
9 Cheatum DE, Arvanitakis C, Gumpel M et al. An endoscopic
study of gastroduodenal lesions induced by nonsteroidal anti-
inﬂammatory drugs. Clin Ther 1999; 21: 992–1003.
10 Laine L, Bombardier C, Hawkey CJ et al. Stratifying the risk
of NSAID-related upper gastrointestinal clinical events: results
of a double-blind outcomes study in patients with rheumatoid
arthritis. Gastroenterology 2002; 123: 1006–12.
11 Higham J, Kang JY, Majeed A. Recent trends in admissions and
mortality due to peptic ulcer in England: increasing frequency
of haemorrhage among older subjects. Gut 2002; 50: 460–4.
12 Lazzaroni M, Bianchi Porro G. Prophylaxis and treatment of
non-steroidal anti-inﬂammatory drug-induced upper gastroin-
testinal side-effects. Dig Liver Dis 2001; 33 (Suppl. 2): S44–
58.
13 Bombardier C, Laine L, Reicin A et al. Comparison of upper
gastrointestinal toxicity of rofecoxib and naproxen in patients
with rheumatoid arthritis. VIGOR Study Group. N Eng J
Med 2000; 343: 1520–8.
14 Goldstein JL, Silverstein FE, Agrawal NM et al. Reduced risk of
upper gastrointestinal ulcer complications with celecoxib, a
novel COX-2 inhibitor. Am J Gastroenterol 2000; 95: 1681–90.
15 Hawkey CJ, Skelly MM. Gastrointestinal safety of selective
COX-2 inhibitors. Curr Pharm Des 2002; 18: 1077–89.
16 Langman MJ, Jensen DM, Watson DJ et al. Adverse upper
gastrointestinal effects of rofecoxib compared with NSAIDs.
JAMA 1999; 282: 1929–33.
1406 RANITIDINE THERAPY FOR HEALING PEPTIC ULCERS
ª 2006 The Authors
Journal compilation ª 2006 Blackwell Publishing Ltd Int J Clin Pract, November 2006, 60, 11, 1401–140717 U.S. Food and Drug Administration Center for Drug Evalua-
tion and Research. Public Health Advisory Non-Steroidal Anti-
Inﬂammatory Drug Products. December 23, 2004. Available at:
http://www.fda.gov/cder/drug/advisory/nsaids.htm (accessed
July 7, 2005).
18 Cullen D, Bardhan KD, Eisner M et al. Primary gastroduode-
nal prophylaxis with omeprazole for non-steroidal anti-inﬂam-
matory drug users. Aliment Pharmacol Ther 1998; 12: 135–40.
19 Yeomans ND, Tulassay Z, Juhasz L et al. A comparison of
omeprazole with ranitidine for ulcers associated with nonste-
roidal antiinﬂammatory drugs. Acid Suppression Trial: Raniti-
dine versus Omeprazole for NSAID-associated Ulcer
Treatment (ASTRONAUT) Study Group. N Engl J Med
1998; 338: 719–26.
20 Hawkey CJ, Karrasch JA, Szczepanski L et al. Omeprazole com-
pared with misoprostol for ulcers associated with nonsteroidal
anti-inﬂammatory drugs. N Engl J Med 1998; 338: 727–34.
21 Bianchi Porro G, Lazzaroni M, Imbesi V et al. Efﬁcacy of
pantoprazole in the prevention of peptic ulcers, induced by
non-steroidal anti-inﬂammatory drugs: a prospective, placebo-
controlled, double-blind, parallel-group study. Dig Liver Dis
2000; 32: 201–8.
22 Scheiman JM, Yeomans ND, Talley NJ et al. Prevention of
ulcers by esomeprazole in at-risk patients using non-selective
NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006;
101: 701–10.
23 Weaver AL, Gitlin N. Ulcer prevention in long-term users of
nonsteroidal anti-inﬂammatory drugs. Arch Intern Med 2002;
162: 169–775.
24 Silverstein FE, Graham DY, Senior JR et al. Misoprostol redu-
ces serious gastrointestinal complications in patients with rheu-
matoid arthritis receiving non-steroidal anti-inﬂammatory
drugs. A randomized, double blind placebo controlled trial.
Ann Intern Med 1995; 123: 241–9.
25 Hunt RH. The relationship between the control of pH and
healing and symptom relief in gastro-oesophageal reﬂux dis-
ease. Aliment Pharmacol Ther 1995; 9 (Suppl. 1): 3–7.
26 Goldstein JL, Johanson JF, Suchower LJ et al. Healing of gas-
tric ulcers with esomeprazole versus ranitidine in patients who
continued to receive NSAID therapy: a randomized trial. Am J
Gastroenterol 2005; 100: 2650–7.
27 Campbell DR, Haber MM, Sheldon E et al. Effect of H. pylori
status on gastric ulcer healing in patients continuing nonsteroi-
dal anti-inﬂammatory therapy and receiving treatment with lan-
soprazole or ranitidine. Am J Gastroenterol 2002; 97: 2208–14.
28 Agrawal NM, Campbell DR, Safdi MA et al. Superiority of
lansoprazole vs ranitidine in healing nonsteroidal anti-inﬂam-
matory drug-associated gastric ulcers: results of a double-blind,
randomized, multicenter study. NSAID-Associated Gastric
Ulcer Study Group. Arch Intern Med 2000; 160: 1455–61.
29 Tildesley G, Ehsanullah RS, Wood JR. Ranitidine in the treat-
ment of gastric and duodenal ulcers associated with non-steroi-
dal anti-inﬂammatory drugs. Br J Rheumatol 1993; 32: 474–8.
30 Lancaster-Smith MJ, Jaderberg ME, Jackson DA. Ranitidine
in the treatment of non-steroidal anti-inﬂammatory drug asso-
ciated gastric and duodenal ulcers. Gut 1991; 32: 252–5.
31 Manniche C, Malchow-Moller A, Andersen JR et al. Random-
ised study of the inﬂuence of non-steroidal anti-inﬂammatory
drugs on the treatment of peptic ulcer in patients with rheu-
matic disease. Gut 1987; 28: 226–9.
32 Hudson N, Taha AS, Russell RI et al. Famotidine for healing
and maintenance in nonsteroidal anti-inﬂammatory drug-asso-
ciated gastroduodenal ulceration. Gastroenterology 1997; 112:
1817–22.
33 Simon B, Muller P. Nizatidine in therapy and prevention of
non-steroidal anti-inﬂammatory drug-induced gastroduodenal
ulcer in rheumatic patients. Scand J Gastroenterol Suppl 1994;
206: 25–8.
34 Bijlsma JW. Treatment of NSAID-induced gastrointestinal
lesions with cimetidine: an international multicentre collaborat-
ive study. Aliment Pharmacol Ther 1988; 2 (Suppl. 1): 85–95.
35 Brodie DA, Chase BJ. Role of gastric acid in aspirin-induced
irritation in the rat. Gastroenterology 1967; 53: 604–10.
36 Elliott SL, Ferris RJ, Giraud AS et al. Indomethacin damage
to rat gastric mucosa is markedly dependent on luminal pH.
Clin Exp Pharmacol Physiol 1996; 23: 432–4.
37 Plachetka J, Morelli G, Hines C et al. Integrated gastric acid-
ity can predict the prevention of naproxen-induced gastroduo-
denal pathology in normal subjects. Gastroenterology 2003;
124 (Suppl. 1): A510.
38 Bell NJ, Hunt RH. Progress with proton pump inhibition.
Yale J Biol Med 1992; 65: 649–57.
39 Chiverton SG, Hunt RH. Relationship between inhibition of
acid secretion and healing of peptic ulcers. Scand J Gastroenter-
ol Suppl 1989; 166: 43–7.
40 Yeomans ND, Garas G, Hawkey CJ. The non-steroidal anti-
inﬂammatory drugs controversy. Gastroenterol Clin North Am
2000; 29: 791–805.
41 Ford A, Delaney B, Forman D et al. Eradication therapy for
peptic ulcer disease in Helicobacter pylori positive patients.
Cochrane Database Syst Rev 2004; 4: CD003840.
42 Labenz J, Tillenburg B, Peitz U et al. Helicobacter pylori aug-
ments the pH-increasing effect of omeprazole in patients with
duodenal ulcer. Gastroenterology 1996; 110: 725–32.
43 Hudson N, Balsitis M, Filipowicz F et al. Effect of Helicobact-
er pylori colonisation on gastric mucosal eicosanoid synthesis
in patients taking non-steroidal anti-inﬂammatory drugs. Gut
1993; 34: 748–51.
44 Ivey KJ. Mechanisms of nonsteroidal anti-inﬂammatory drug-
induced gastric damage: actions of therapeutic agents. Am J
Med 1998; 84 (Suppl. 2A): 41–8.
45 Allen A, Flemstrom G. Gastroduodenal mucus bicarbonate
barrier: protection against acid and pepsin. Am J Physiol Cell
Physiol 2005; 288: C1–19.
Paper received June 2006, accepted July 2006
RANITIDINE THERAPY FOR HEALING PEPTIC ULCERS 1407
ª 2006 The Authors
Journal compilation ª 2006 Blackwell Publishing Ltd Int J Clin Pract, November 2006, 60, 11, 1401–1407